UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~ 23September 9, 2021

GENETHERA, INC. (Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)

Nevada

000-27237

65-0622463

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Nevada	000-27237	65-0622463
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3051 W 105th Ave. Westminster, CO		80031
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (720) 587-5100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~☐ Soliciting~~Securities ~~material~~registered pursuant to ~~Rule~~Section ~~14a-12~~12b ~~under~~of the ~~Exchange Act (17 CFR 240.14a-12)~~act

~~☐ Pre-commencement~~Title ~~communications~~of ~~pursuant~~each toStocks ~~Rule~~Trading ~~14d-2(b)~~Symbol ~~under~~Name of the Exchange ~~Act (17~~which ~~CFR~~registered ~~240.14d-2(b))~~ Common StocksPreferred APreferred B GTHR OTCMK

~~☐ Pre-commencement~~Indicate ~~communications~~by ~~pursuant~~check tomark whether the registrant is an emerging company as defined in Rule ~~13e-4~~405 of the Security act of 1933 (c230.405 of this chapter) ~~under~~or Rule 12b-2 of the Securities Exchange Act ~~(17~~ of ~~CFR~~1934 (240.~~13e-4(c~~12bof this chapter))

1Emerging growth company ☐

~~ITEM~~If ~~10.1~~an ~~GENETHERA~~emerging growth company, ~~INC.~~indicate ~~INCORPORATES~~by ~~SUBSIDIARY~~check INmark ~~THE~~if ~~UNITED~~the ~~KINGDOM~~registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to section 13(a) of the Exchange Act. ☐

OnITEM ~~April 23, 2021 GeneThera Inc~~1. ~~received confirmation from The Registrar of Companies for England and Wales that GeneThera’s subsidiary, GeneThera Robotics Limited~~01., ~~has~~ENTRY ~~been~~INTO registered in the United Kingdom. The ownership of the subsidiary is designated as followed: GeneThera Inc fifty-one percentage; Alejandra Baglietto forty-nine percentage. On the same day GeneThera Board of Directors approved the appointment of Mrs. Alejandra Baglietto as Managing Director of GeneThera Robotics Ltd. GeneThera Inc subsidiary will be responsible for the UK and International operations related to the development of the Zoonotic Infectious Diseases Alert Shield (ZIDAS) platform. Mrs. Baglietto holds a B.A. ~~and~~MATERIAL ~~M.A.~~DEFINITIVE from Cal State University at San Bernardino. She has worked both in the private and public sector and has experience dealing with government and business relations, clients, communications and investments. Mrs. Baglietto has worked with numerous private and public companies, most recently, assisting with assessing political risk, international trade investments and ministry of finance guarantees. AGREEMENT

~~Item~~GENETHERA, 9INC.01 ~~EXHIBITS~~AND CUSHMAN&WAKE FIELD ENTERED INTO A CONSULTING AGREEMENT

On September 9, 2021 GeneThera Inc. entered into a representation agreement with Cushman and Wakefield Us Inc. According to the terms on the agreement, Cushman and Wake field will represent GeneThera Inc in any transaction related to the acquisition of land in connection with to the construction of GeneThera’s Biosafety Level 3 (BSL-3) laboratory facilities to be used as molecular robotic diagnostic therapeutic and research facilities for SARS-CoV-2 and other zoonotic diseases. Additionally Cushman & Wakefield will represent GeneThera in any transaction to secure warehouse space related to GeneThera assembly and storage of mobile laboratory units for the development of the wastewater surveillance network. Scope of the services and fees are outlined in Exhibit ~~Number~~A ~~Description~~attached to the Agreement. GeneThera Inc appoints Cushman & Wakefield as its sole agent and grants Cushman &Wakefield the exclusive right to represent GeneThera in any real estate transaction related to the Company Zoonotic Infectious Disease Alert Shield (ZIDAS) project.

10ITEM 9.101. ~~Incorporation~~FINANCIAL ~~Documents~~STATEMENTS AND EXHIBITS

. Exhibit A

Exhibit Number		Description

10.1		Collaboration Agreement

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~Exhibit B~~2

2SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

	GeneThera, Inc., a Nevada Corporation

Date: October 12, 2021	By:	/s/ Antonio Milici
		Antonio Milici
		CEO

~~GeneThera, Inc., a Nevada Corporation By:/s/ Antonio Milici Antonio Milici, CEO~~3

Date: May 18, 2021

Filing Compare · GENETHERA INC